Skip to main content

Illinois IGB

Timothy Fan

Immunotherapy Trials Show Promise for Treating Canine Melanoma

August 9, 2022

Dr. Timothy Fan (ACPP), veterinary oncologist and professor at the University of Illinois College of Veterinary Medicine and a Program Leader for the Cancer Center at Illinois, is leading two clinical trials using similar immunotherapies to treat dogs with malignant melanoma. The novel approaches, developed in partnership with cancer researchers based in Boston, have yielded encouraging results in canine patients, and human trials using the same therapeutic platforms are expected to begin in 2023.


August 9, 2022


Related Articles

SHIELD program a model for effective pandemic management, data show

June 13, 2022

In the fall of 2020, the University of Illinois Urbana-Champaign welcomed students back for in-person instruction amid the powerful first wave of the COVID-19 pandemic. The university successfully maintained operations throughout the semester – with zero COVID-19-related deaths or hospitalizations in the campus community – thanks to its “SHIELD: Target, Test, Tell” program.


June 13, 2022


Related Articles

15 Years of IGB: SHIELDing the Illinois community against COVID-19

May 11, 2022

During the earliest months of 2020, COVID-19 seemed like an innocuous event that was too geographically distant to affect the Illinois community. In fact, by March 10th there were only 19 confirmed cases. Nevertheless, Nigel Goldenfeld (BCXT leader/GNDP), former Swanlund Endowed Chair and professor of physics, and Sergei Maslov (BCXT/CABBI), a professor of bioengineering and Bliss Faculty Scholar, were worried. The news from China and Italy was concerning and in four days a significant portion of students, faculty, and staff were going to leave for spring break.


May 11, 2022


Related Articles

10 IGB members receive Presidential Medallion

August 23, 2021

August 23, 2021


Related Articles

Chancellor, Provost offer reflections on 1 million COVID-19 tests

December 15, 2020

It sometimes seems a million doesn’t command quite the same attention that it used to. It isn’t mathematically special. And in today’s society, it isn’t even unusually large. We now live in a world where the population is measured in billions, economies are scaled in trillions and computer calculations are counted by the quadrillion.

But it takes on a very special significance when you’re talking about looking after the well-being of your community in the middle of a globally devastating pandemic.


December 15, 2020


Related Articles

Cancer compound leads to major licensing deal

October 6, 2020

Researchers affiliated with the Cancer Center at Illinois and the IGB discovered a novel small molecule compound that is now the subject of a new global licensing agreement between the pharmaceutical company Bayer AG and the cancer drug development company Systems Oncology LLC. Systems Oncology originally licensed the IP related to the compound in 2018, and this new deal will now give Bayer the exclusive rights to develop the compound, currently called ERSO, as a cancer therapy.


October 6, 2020


Related Articles

Molecular probe illuminates elusive cancer stem cells in live mice

August 2, 2018

After a primary tumor is treated, cancer stem cells may still lurk in the body, ready to metastasize and cause a recurrence of the cancer in a form that’s more aggressive and resistant to treatment. University of Illinois researchers have developed a molecular probe that seeks out these elusive cells and lights them up so they can be identified, tracked and studied not only in cell cultures, but in their native environment: the body.


August 2, 2018


Related Articles

Cancer drug starts clinical trials in human brain-cancer patients

November 27, 2017

A drug that spurs cancer cells to self-destruct has been cleared for use in a clinical trial of patients with anaplastic astrocytoma, a rare malignant brain tumor, and glioblastoma multiforme, an aggressive late-stage cancer of the brain. This phase Ib trial will determine if the experimental drug PAC-1 can be used safely in combination with a standard brain-cancer chemotherapy drug, temozolomide.


November 27, 2017


Related Articles

Subscribe to Timothy Fan